ASC4OPT研究:asciminib治疗经≥2种TKI治疗的慢性期慢性髓性白血病患者
ASC4OPT是一项非比较性3b期研究,纳入169例经≥2种TKI治疗、按ELN 2020标准疗效不满意或对最近TKI不耐受且基线达MMR的CML-CP患者,评估asciminib每日一次或两次给药。基线未达MMR患者第48周总体MMR率为39.4%,第96周为43.6%;基线达MMR者多数维持MMR。安全性与此前研究一致。
要点
- 基线未达MMR患者第48周MMR率39.4%,第96周43.6%
- 40 mg BID与80 mg QD两方案MMR率相近,安全性一致
- 基线达MMR者第48周93.3%、第96周86.7%维持MMR
核心结论
- asciminib可能成为经≥2种TKI治疗后疗效不佳的CML-CP患者的标准治疗选择。
研究设计与样本
- ASC4OPT为非比较性3b期研究(NCT04948333),纳入169例经≥2种TKI治疗的CML-CP患者。
- 患者按ELN 2020标准为疗效不满意(不耐受、警告或失败),另纳入30例对最近TKI不耐受且基线达MMR者。
主要发现
- 基线未达MMR患者第48周总体MMR率为39.4%(40 mg BID 43.4%;80 mg QD 35.4%)。
- 基线未达MMR患者第96周MMR率为43.6%(40 mg BID 45.8%;80 mg QD 41.5%)。
- 40例asciminib剂量升至200 mg QD者中,17.5%在第96周达MMR。
- 基线达MMR患者第48周和第96周维持MMR的比例分别为93.3%和86.7%。
- 两种给药方案的安全性与此前研究一致。
关键数值与推荐
- 主要终点为基线未达MMR患者第48周的MMR率。
- MMR率:第48周总体39.4%(40 mg BID 43.4%;80 mg QD 35.4%)。
- MMR率:第96周总体43.6%(40 mg BID 45.8%;80 mg QD 41.5%)。
- 剂量升至200 mg QD者第96周MMR率17.5%。
- 基线达MMR者第48周和96周维持MMR率分别为93.3%和86.7%。
临床怎么用
- 对于经≥2种TKI治疗未达最佳反应的CML-CP患者,可考虑asciminib 40 mg BID或80 mg QD。
- 对最近TKI不耐受且已达MMR者,asciminib可维持MMR。
- 剂量可升至200 mg QD,但升至该剂量后第96周MMR率有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ASC4OPT non-comparative phase 3b study (NCT04948333) evaluates asciminib once daily (QD) or twice daily (BID) in chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 tyrosine kinase inhibitors (TKIs). This study enrolled 169 patients not in major molecular response (MMR), with unsatisfactory response (intolerant, warning or failure) as defined by European LeukemiaNet (ELN) 2020 criteria. Patients intolerant to their most recent TKI and in MMR at baseline (n = 30) were also enrolled. The primary endpoint was the MMR rate at Week 48 for patients not in MMR at baseline. Results showed an overall MMR rate of 39.4% at Week 48 (40 mg BID, 43.4%; 80 mg QD, 35.4%) and 43.6% at Week 96 (40 mg BID, 45.8%; 80 mg QD, 41.5%) in patients not in MMR at baseline. Among 40 patients who had their asciminib dose escalated to 200 mg QD, 17.5% were in MMR at Week 96. Most patients in MMR at baseline remained in MMR at 48 and 96 weeks (93.3% and 86.7%, respectively). Safety for both dosing regimens was consistent with that of previous studies. Findings support asciminib as a potential standard of care for patients with CML-CP who have not responded optimally to prior TKI therapy.
引用
- Hochhaus A, le Coutre P, Milojkovic D, et al. ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. Leukemia. 2026. PMID: 42026180. doi:10.1038/s41375-026-02965-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。